A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study shows.
Apr 9, 2024
0
64
Relapses in a common form of leukemia may be preventable following new research that has identified how the cancer develops resistance to first line treatments.
Apr 9, 2024
0
3
Researchers have identified new variations in neuroblastoma that could lead to a more accurate prognosis and better-targeted treatments for this devastating childhood cancer.
Apr 9, 2024
0
27
Drugs known as GLP-1 analogs have become increasingly popular to treat diabetes and obesity, but there have been concerns that they might increase the risk of thyroid cancer. Now an extensive Scandinavian study led by researchers ...
Apr 9, 2024
0
28
A recent Northwestern Medicine study has discovered a previously unknown molecular mechanism that supports antitumor responses and cell survival in cytotoxic immune cells, according to findings published in the Journal of ...
Apr 9, 2024
0
1
Health care cost and access are not the only barriers women face in getting lifesaving mammograms, a new government report finds.
Apr 9, 2024
0
0
Are you one of the estimated 104,000 Americans who lives within six miles of factories that spew organic chemicals into the air?
Apr 9, 2024
0
0
A blood-based machine learning assay that combines cell-free DNA (cfDNA) fragment patterns and levels of the proteins CA125 and HE4 could differentiate patients with ovarian cancer from healthy controls or patients with benign ...
Apr 9, 2024
0
0
A new article in JBMR Plus indicates that patient survival rates after hip or other bone fractures can be very poor. While patients and their families may dismiss a fracture as a minor injury, survival rates can be lower ...
Apr 9, 2024
0
1
About 90% of deaths from cancer are a result of metastasis—that is, from cancer's ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain.
Apr 9, 2024
0
0
